Literature DB >> 9799993

The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro.

A Cervin1, S Lindgren.   

Abstract

Bronchodilatory substances such as the phosphodisterase inhibitor (PDE-I) theophylline stimulate mucociliary activity. With the introduction of selective PDE-Is it has become possible to study the functional importance of each phosphodiesterase enzyme (PDE) concerning the regulation of the ciliary beat. The effects of rolipram (inhibiting a cAMP specific PDE (PDE4), milrinone (inhibiting a cGMP inhibited PDE (PDE3)) and zaprinast (inhibiting a cGMP specific PDE (PDE5)) were investigated in in vitro preparations from the rabbit maxillary sinus and trachea. Ciliary beat frequency (CBF) was measured with a photoelectrical method. In sinus mucosa all three compounds accelerated CBF. Milrinone (10(-5) M) by 22.6 +/- 5.3% (n = 6; P < 0.01), rolipram (10(-5) M) by 29.7 +/- 5.7% (n = 7; P < 0.01), and zaprinast (10(-5) M) by 19.4 +/- 6.3% (n = 6; P < 0.05). In the tracheal specimens at a concentration of 10(-5) M, milrinone accelerated CBF by 27.5 +/- 9.0% (n = 7; < 0.05), rolipram by 11.6 +/- 2.8% (n = 6; P < 0.05) and zaprinast by 24.3 +/- 5.3% (n = 7; P < 0.01). Comparison of the effects in the upper and lower airways showed that at concentrations of 10(-5) and 10(-4) M rolipram was more effective in the upper than in the lower airways. The reverse was true of milrinone which concentrations of 10(-7) and 10(-6) M had a significant effect in tracheal specimens but not in sinus specimens. Zaprinast was equally effective in both the upper and lower airways. It is concluded that in both the upper and lower airways selective PDE-Is have an accelerating effect on the CBF that may be beneficial in the treatment of airway diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9799993     DOI: 10.1016/s0385-8146(98)00010-8

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  4 in total

1.  Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

Authors:  J Milara; M Armengot; P Bañuls; H Tenor; Rolf Beume; E Artigues; J Cortijo
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Oral enoximone allows the reduction and discontinuation of inhaled steroids and beta2 agonists in asthmatic children.

Authors:  Jan Beute; Alex KleinJan
Journal:  Int J Pediatr Adolesc Med       Date:  2021-02-19

Review 3.  Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors.

Authors:  Marta Joskova; Juraj Mokry; Sona Franova
Journal:  Front Pharmacol       Date:  2020-05-06       Impact factor: 5.810

4.  PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia.

Authors:  Jan Beute; Pieter Boermans; Bart Benraad; Jan Telman; Zuzana Diamant; Alex KleinJan
Journal:  Exp Lung Res       Date:  2021-02-05       Impact factor: 2.459

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.